Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,900,000 Class A Ordinary Shares of Cantor Equity Partners I, Inc. as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 683,662 Class A Ordinary Shares of NMP Acquisition Corp., representing 5.6% of the class, as of a triggering event dated September 30, 2026.
Highbridge Capital Management, LLC filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing an 8.1% stake in Nuburu, Inc. based on 819,821 shares of common stock issuable upon exercise of warrants held by Highbridge-managed funds.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 4,761,905 shares of Cardiff Oncology, Inc. common stock issuable upon exercise of warrants, representing 5.8% of the class as of September 30, 2026.
Highbridge Capital Management, LLC filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing that it holds zero ordinary shares of Futurewave Acquisition Corporation as of September 30, 2026.
RTW Investments, LP and its Managing Partner Roderick Wong filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 5,905,426 shares of Solid Biosciences Inc. common stock as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 814,229 Class A Ordinary Shares of Harvard Ave Acquisition Corporation as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of ordinary shares of LaFayette Acquisition Corp. as of September 30, 2026.
Highbridge Capital Management, LLC filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing that it holds zero ordinary shares of Peace Acquisition Corp. as of September 30, 2026.
Highbridge Capital Management, LLC filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,454,400 shares of INmune Bio, Inc. common stock issuable upon exercise of warrants held by Highbridge-managed funds.